Developing novel vaccines to cure HIV infection

Read more
HTI immunogen: a new therapeutic vaccine against HIV
Approach

HTI immunogen: a new therapeutic vaccine against HIV

The HTI immunogen was discovered by Dr. Christian Brander, CSO of AELIX Therapeutics, and co-workers. It is based on the observation that T-cell responses to certain HIV regions are enriched in individuals with enhanced control of their HIV-infection. The HTI immunogen brings these beneficial regions together as a vaccine immunogen…

More
WHO WE ARE

Meet the team

AELIX Therapeutics is a biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be used in cure/eradication strategies. Aelix Therapeutics is a spin-off of HIVACAT, a Catalan public-private consortium conducting cutting-edge research in this field.

More

Whats new?

May 18, 2021

AELIX Therapeutics appoints Dr Melanie Rolli as CEO

Read more

March 10, 2021

AELIX has presented positive results from the clinical study AELIX-002 at the 2021 Conference on Retroviruses and Opportunistic Infections (CROI)

Read more

March 10, 2021

Abstract of the oral presentation of the AELIX-002 study results at the 2021 Conference on Retroviruses and Opportunistic Infections (CROI)

Read more
More

Testimonials